摘要
目的分析医院免疫增强药物的使用情况,为合理用药提供依据。方法应用金额排序法和用药频度(DDDs)分析法,统计分析医院2011年至2013年临床使用的免疫增强药物。结果 2011年至2013年免疫增强药物的销售金额和限定日剂量逐年上升。核糖核酸Ⅱ的销售金额始终居首位,乌苯美司排在最后,脾氨肽的销售金额增长幅度最大,甘露聚糖肽则出现了下滑;DDDs稳居首位的是胸腺五肽,静注人免疫球蛋白排在最后;各药限定日费用均有所变化,胸腺五肽逐年下降,胸腺肽α1逐年上升,其余各药变化较小,总体稳定;药品销售金额排序/DDDs排序(B/A)最高的为胸腺五肽,最低的为核糖核酸Ⅱ,2012年至2013年甘露聚糖肽与胸腺肽α1均为1.00。结论医院免疫增强药物的使用基本合理,但用量逐年增加,存在不合理用药情况,需进一步加强管理。
Objective To analyze the utilization of immune- enhancing drugs in the hospital and provide evidence for the rational use of these drugs. Methods The amount of sorting method and DDDs method were used to statistically analyze the clinical use of immune-enhancing drugs in our hospital from 2011 to 2013. Results The amount of sales and DDDs of immune- enhancing drugs in the hospital had increased year by year. For the latest 3 years,the sales amount of RNA Ⅱ was always in the first place,ubenimex came in last, the sales amount of spleen aminopeptidaset increased mostly, while mannatides were running down; Thymopentin ranked first in DDDs, and intravenous human immunoglobulin came in last; all drugs had changes with DDC, among which thymopentin had declined year by year,while thymosin α1 had increased year by year,small changes were found in the other drugs,and with overall stability; thymopentin had the highest B / A value,and RNA Ⅱ had the lowest B / A value,mannatide and thymosin α1 had a B / A value closer to 1. 00. Conclusion The utilization of immune- enhancing drug in the hospital is reasonable,but the amount is increasing every year,accompanied by irrational drug use,which needs a better management.
出处
《中国药业》
CAS
2016年第1期72-74,共3页
China Pharmaceuticals
